Insulet EBITDA Margin 2010-2024 | PODD
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Insulet (PODD) over the last 10 years. The current EBITDA margin for Insulet as of December 31, 2024 is .
| Insulet EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-12-31 |
$2.07B |
$0.39B |
18.81% |
| 2024-09-30 |
$1.99B |
$0.38B |
19.35% |
| 2024-06-30 |
$1.87B |
$0.35B |
18.62% |
| 2024-03-31 |
$1.78B |
$0.32B |
18.18% |
| 2023-12-31 |
$1.70B |
$0.29B |
17.26% |
| 2023-09-30 |
$1.56B |
$0.21B |
13.35% |
| 2023-06-30 |
$1.47B |
$0.15B |
10.44% |
| 2023-03-31 |
$1.37B |
$0.09B |
6.80% |
| 2022-12-31 |
$1.31B |
$0.10B |
7.74% |
| 2022-09-30 |
$1.24B |
$0.13B |
10.14% |
| 2022-06-30 |
$1.18B |
$0.16B |
13.16% |
| 2022-03-31 |
$1.14B |
$0.21B |
18.21% |
| 2021-12-31 |
$1.10B |
$0.18B |
16.74% |
| 2021-09-30 |
$1.04B |
$0.14B |
13.21% |
| 2021-06-30 |
$1.00B |
$0.12B |
12.46% |
| 2021-03-31 |
$0.96B |
$0.12B |
12.42% |
| 2020-12-31 |
$0.90B |
$0.11B |
11.73% |
| 2020-09-30 |
$0.87B |
$0.12B |
13.26% |
| 2020-06-30 |
$0.83B |
$0.11B |
12.73% |
| 2020-03-31 |
$0.78B |
$0.08B |
10.57% |
| 2019-12-31 |
$0.74B |
$0.08B |
10.57% |
| 2019-09-30 |
$0.69B |
$0.07B |
10.37% |
| 2019-06-30 |
$0.65B |
$0.06B |
8.88% |
| 2019-03-31 |
$0.60B |
$0.05B |
8.67% |
| 2018-12-31 |
$0.56B |
$0.04B |
7.80% |
| 2018-09-30 |
$0.53B |
$0.03B |
4.91% |
| 2018-06-30 |
$0.50B |
$0.02B |
4.19% |
| 2018-03-31 |
$0.49B |
$0.01B |
2.67% |
| 2017-12-31 |
$0.47B |
$0.01B |
1.51% |
| 2017-09-30 |
$0.44B |
$0.00B |
0.68% |
| 2017-06-30 |
$0.41B |
$0.00B |
0.73% |
| 2017-03-31 |
$0.39B |
$0.01B |
1.29% |
| 2016-12-31 |
$0.37B |
$0.00B |
0.82% |
| 2016-09-30 |
$0.35B |
$0.00B |
-1.15% |
| 2016-06-30 |
$0.32B |
$-0.02B |
-6.50% |
| 2016-03-31 |
$0.30B |
$-0.03B |
-11.11% |
| 2015-12-31 |
$0.26B |
$-0.03B |
-12.50% |
| 2015-09-30 |
$0.20B |
$-0.02B |
-10.77% |
| 2015-06-30 |
$0.20B |
$-0.01B |
-5.03% |
| 2015-03-31 |
$0.21B |
$0.00B |
-0.95% |
| 2014-12-31 |
$0.23B |
$0.00B |
1.30% |
| 2014-09-30 |
$0.29B |
$0.00B |
0.70% |
| 2014-06-30 |
$0.27B |
$-0.01B |
-4.43% |
| 2014-03-31 |
$0.26B |
$-0.01B |
-5.02% |
| 2013-12-31 |
$0.25B |
$-0.02B |
-6.88% |
| 2013-09-30 |
$0.24B |
$-0.02B |
-9.75% |
| 2013-06-30 |
$0.23B |
$-0.02B |
-6.52% |
| 2013-03-31 |
$0.22B |
$-0.02B |
-9.05% |
| 2012-12-31 |
$0.21B |
$-0.03B |
-11.79% |
| 2012-09-30 |
$0.20B |
$-0.03B |
-14.93% |
| 2012-06-30 |
$0.19B |
$-0.03B |
-16.23% |
| 2012-03-31 |
$0.17B |
$-0.04B |
-20.93% |
| 2011-12-31 |
$0.15B |
$-0.03B |
-22.37% |
| 2011-09-30 |
$0.13B |
$-0.04B |
-30.08% |
| 2011-06-30 |
$0.11B |
$-0.04B |
-33.63% |
| 2011-03-31 |
$0.10B |
$-0.03B |
-30.77% |
| 2010-12-31 |
$0.10B |
$-0.03B |
-35.05% |
| 2010-09-30 |
$0.09B |
$-0.03B |
-32.58% |
| 2010-06-30 |
$0.08B |
$-0.04B |
-42.17% |
| 2010-03-31 |
$0.08B |
$-0.04B |
-54.67% |
| 2009-12-31 |
$0.07B |
$-0.05B |
-72.73% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED PRODUCTS |
$17.608B |
$2.072B |
|
Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.
|
